CONTINUOUS MEDICAMENT SENSOR SYSTEM FOR IN VIVO USE

• US 20090299156A1
• Filed: 02/04/2009
• Published: 12/03/2009
• Est. Priority Date: 02/20/2008
• Status: Abandoned Application

• Current Assignee: DexCom Incorporated
• Original Assignee: DexCom Incorporated
• Inventors: McCarthy, Eleanor, Matsubara, Bradley Shigeto, Boock, Robert, Brister, Mark, Simpson, Peter C., Yang, Richard C.
• Application Number:
  US12/365,683
• Publication Number:
  US 20090299156A1
• Time in Patent Office: Days
• US Class Current: 600/301
• CPC Class Codes: A61B 5/0002 Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network A61B5/07 takes precedence; transmission systems for measured values G08C; transmission H04B; transmission of digital information H04L; wireless communication networks H04W
• CPC Class Codes: A61B 5/064 using markers A61B5/062 takes precedence
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61B 5/411 Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61M 2005/14296 Pharmacokinetic models
• CPC Class Codes: A61M 2230/201 Glucose concentration
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00

Abstract

Systems and methods for continuous measurement of a medicament in vivo are provided. In some embodiments, the system is configured to provide information associated with medicament titration and includes a continuous analyte sensor and a communication device. In some embodiments, the system is configured for continuous ambulatory drug testing, including an ambulatory host monitor having a continuous sensor, a location module, a processor module and a transmitter. In some embodiments, the system is configured for continuously monitoring a hormone level and includes a continuous hormone sensor and a communication device configured to output hormone information in real time. Yet another embodiment provides an analyte sensor for continuous monitoring of a host'"'"'s nutritional status, and is configured for both continuous glucose detection and continuous albumin detection.

Claims

1. A system for providing information associated with a titration of a medicament in a host, comprising:

a continuous analyte sensor configured to detect a first signal associated with a medicament concentration in vivo in a host; and

a communication device comprising an input module configured to receive titration parameters, and a processor module configured to process the first signal and the titration parameters to obtain titration information associated with a titration of the medicament, wherein the communication device is configured to output the titration information.

2. The system of claim 1, wherein the titration parameters comprise at least one parameter selected from the group consisting of medicament identity information, a target medicament concentration, a medicament concentration limit, a toxic medicament concentration, a medicament delivery rate, a medicament delivery time, host data, and medicament effect information.

3. The system of claim 2, wherein the processor module is configured to provide an alarm when the medicament concentration is substantially within a predetermined percentage of the medicament concentration limit.

4. The system of claim 1, wherein the titration information comprises at least one member selected from the group consisting of a current medicament concentration, a predicted medicament concentration, a change in medicament concentration, an acceleration of medicament concentration, a relationship of medicament concentration and a medicament concentration limit, rate of change information, a clearance rate, and a correlation between a medicament concentration and a medicament effect experienced by the host.

5. The system of claim 1, wherein the information comprises at least one member selected from the group consisting of a therapy recommendation and a therapy instruction.

6. The system of claim 1, wherein the input module is further configured to receive a second signal associated with an effect of the medicament, and wherein the processor module is further configured to process the first signal, the second signal and the titration parameters to obtain the titration information.

7. The system of claim 6, further comprising a secondary medical device.

8. The system of claim 7, wherein the secondary medical device comprises at least one device selected from the group consisting of a secondary analyte sensor and a patient monitor, wherein the secondary medical device is configured to detect a second signal associated with an effect of a delivered medicament.

9. The system of claim 8, wherein the effect of the delivered medicament is associated with a change in a host physical attribute.

10. The system of claim 8, wherein the medicament comprises an anti-multiple sclerosis medicament, and wherein the effect of the delivered medicament comprises a change in at least one member selected from the group consisting of a multiple sclerosis symptom and a side effect of the anti-multiple sclerosis medicament.

11. The system of claim 8, wherein the medicament comprises an anti-epilepsy medicament, and wherein the effect of the delivered medicament comprises a change in at least one member selected from the group consisting of an epilepsy symptom and a side effect of the anti-epilepsy medicament.

12. The system of claim 1, wherein the communication device is configured to output the titration information to a secondary medical device.

13. The system of claim 12, wherein the secondary medical device comprises an anesthesia device.

14. The system of claim 12, wherein the secondary medical device comprises a medicament delivery device.

15. The system of claim 12, wherein the secondary medical device is configured to monitor an attribute of the host.

16. The system of claim 1, wherein the processor module is configured to determine an optimal dose of the medicament.

17. The system of claim 1, wherein the communication device comprises a user interface configured to perform at least one of outputting the titration information and receiving titration parameters.

18. A system for continuous ambulatory drug testing, comprising:

an ambulatory host monitor comprising a continuous sensor configured to detect a signal associated with a presence of a drug in vivo in a host, a location module configured to provide a location of the continuous sensor, and a first processor module configured to process the signal to obtain drug information; and

a transmitter configured to transmit the drug information.

19. The system of claim 18, further comprising a communication device located remotely from the ambulatory host monitor, wherein the communication device is configured to receive the drug information and the location, and to process the drug information and the location to obtain drug-monitoring information, and wherein the communication device is configured to output the drug-monitoring information.

20. The system of claim 19, wherein the drug-monitoring information comprises at least one of an instruction and a recommendation.

21. The system of claim 18, wherein the first processor module is configured to provide an alarm when the signal is below a programmed level.

22. The system of claim 18, wherein the drug is a drug of abuse and wherein drug information comprises information associated with a presence of the drug of abuse in the host.

23. The system of claim 18, wherein the drug is a medicament and the drug information comprises information associated with a presence of the medicament in the host.

24. The system of claim 23, wherein the medicament comprises an anti-tuberculosis medicament.

25. The system of claim 18, further comprising a secondary device configured to operably connect with the ambulatory host monitor, wherein the ambulatory host monitor is further configured to provide drug information to the secondary device, and wherein the secondary device is configured to perform at least one of providing an alert and deactivating a machine.

26. The system of claim 18, wherein the continuous sensor is a transcutaneous continuous sensor.

27. A system for continuously monitoring a hormone level, comprising:

a continuous hormone sensor configured to detect a signal associated with a hormone concentration in vivo in a host; and

a communication device comprising a processor module configured to process the signal to provide hormone information, wherein the communication device is configured to output the hormone information in real time.

28. The system of claim 27, wherein communication device is further configured to store the hormone information over time, and wherein the processor module is further configured to process the stored hormone information and the real-time hormone information to provide diagnostic information.

29. The system of claim 28, wherein the hormone is luteinizing hormone, and wherein the diagnostic information comprises a time period associated with ovulation in the host.

30. The system of claim 27, wherein the hormone is human chorionic gonadotropin, and wherein the diagnostic information comprises pregnancy information.

31. The system of claim 27, wherein the sensor is configured to measure a signal associated with at least one hormone selected from the group consisting of luteinizing hormone, estradiol, progesterone, follicle stimulating hormone, follicle stimulating hormone β

subunit, thyroid stimulating hormone, testosterone, and human chorionic gonadotropin.

32. An analyte sensor for monitoring nutritional status in a host, comprising:

a first sensing portion configured to measure a first signal associated with a glucose concentration in a host;

a second sensing portion configured to measure a second signal associated with an albumin concentration in the host; and

a processor module configured to process the first signal and the second signal to obtain nutrition information in vivo.

33. The device of claim 32, wherein the first sensing portion is configured and arranged to measure the first signal using at least one detection method selected from the group consisting of electrochemical detection, immunochemical detection, physical detection, optical detection, radiological detection, chemical detection, and combinations thereof.

34. The device of claim 32, wherein the second sensing portion is configured and arranged to measure the second signal using at least one detection method selected from the group consisting of electrochemical detection, immunochemical detection, physical detection, optical detection, radiological detection, chemical detection, and combinations thereof.

35. The device of claim 32, further comprising an output module configured to output the nutrition information.

36. The device of claim 35, wherein the nutrition information comprises at least one member selected from the group consisting of an analyte concentration, a change in analyte concentration, a rate of change in analyte concentration, a peak analyte concentration, a lowest analyte concentration, a correlation between a glucose concentration and an albumin concentration, nutrition status, and an alarm.